SCHEMBL29630236

SCHEMBL29630236

O=C(O)c1coc2ccc(O)cc12

nearest known ligand 0.66

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SIRT1 Q96EB6 5/20 0.66
ALDH1A1 P00352 2/20 0.64
TSHR P16473 1/20 0.64
NPSR1 Q6W5P4 1/20 0.64
NPC1 O15118 4/20 0.60
MAPT P10636 3/20 0.60
CASP3 P42574 2/20 0.60
SENP7 Q9BQF6 2/20 0.60
SENP6 Q9GZR1 2/20 0.60
RAB9A P51151 2/20 0.60
LMNA P02545 2/20 0.60
HTT P42858 2/20 0.60
SENP8 Q96LD8 1/20 0.60
KMT2A Q03164 1/20 0.60
NFKB1 P19838 1/20 0.60
NFKB2 Q00653 1/20 0.60
RELA Q04206 1/20 0.60
HPGD P15428 2/20 0.57
SMN1; SMN2 Q16637 1/20 0.56
MAOB P27338 5/20 0.55

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3377499 1.00 SIRT1 (0.66) SIRT1ALDH1A1TSHRNPSR1NPC1
SCHEMBL27861098 0.87 SIRT1 (0.84) SIRT1ALDH1A1TSHRNPSR1NPC1
SCHEMBL204082 0.85 PIM1 (0.54) SIRT1ALDH1A1TSHRNPSR1NPC1
SCHEMBL289145 0.82 SIRT1 (0.81) SIRT1ALDH1A1TSHRNPSR1NPC1
SCHEMBL29933496 0.80 MAOB (0.56) ALDH1A1TSHRNPC1MAPTRAB9A
SCHEMBL18936167 0.80 MAOB (0.49) SIRT1ALDH1A1TSHRNPSR1NPC1
SCHEMBL6614160 0.80 KDM4E (0.52) SIRT1ALDH1A1TSHRNPSR1NPC1
SCHEMBL10898831 0.80 MAOB (0.56) ALDH1A1TSHRNPC1MAPTRAB9A
SCHEMBL6840630 0.80 CASP3 (0.55) SIRT1ALDH1A1TSHRNPSR1NPC1
SCHEMBL29933483 0.80 KDM4E (0.52) SIRT1ALDH1A1TSHRNPSR1NPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2025111414-A1 TRPM3-MODULATING BENZOFURAN DERIVATIVES KATHOLIEKE UNIVERSITEIT LEUVEN (BE) 2025-05-30 WO disclosed
EP-4532479-A1 NEW DERIVATIVES FOR TREATING TRPM3 MEDIATED DISORDERS Katholieke Universiteit Leuven KU Leuven Research & Development (BE) 2025-04-09 EP disclosed
US-12209081-B2 Heterocycle derivatives for treating TRPM3 mediated disorders KATHOLIEKE UNIVERSITEIT LEUVEN (BE) 2025-01-28 US disclosed
WO-2023227695-A1 NEW DERIVATIVES FOR TREATING TRPM3 MEDIATED DISORDERS KATHOLIEKE UNIVERSITEIT LEUVEN (BE) 2023-11-30 WO disclosed
EP-4259613-A1 ARYL DERIVATIVES FOR TREATING TRPM3 MEDIATED DISORDERS Katholieke Universiteit Leuven KU Leuven Research & Development (BE) 2023-10-18 EP disclosed
WO-2022112352-A1 HETEROCYCLE DERIVATIVES FOR TREATING TRPM3 MEDIATED DISORDERS KATHOLIEKE UNIVERSITEIT LEUVEN (BE) 2022-06-02 WO disclosed
WO-2022112345-A1 ARYL DERIVATIVES FOR TREATING TRPM3 MEDIATED DISORDERS KATHOLIEKE UNIVERSITEIT LEUVEN (BE) 2022-06-02 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12209081-B2 Heterocycle derivatives for treating TRPM3 mediated disorders TRPM4, TRPM6, TRPM2 SIRT1 732/4885ALDH1A1 2383/4885TSHR 3289/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.